Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 12 options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $41,820, and 11, calls, for a total amount of $1,067,687.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $60.0 for Viking Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 1909.0 with a total volume of 3,526.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $25.0 to $60.0 over the last 30 days.
Viking Therapeutics Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 12/17/27 | $10.45 | $10.4 | $10.45 | $60.00 | $260.2K | 1.5K | 1.0K |
| VKTX | CALL | TRADE | BULLISH | 01/15/27 | $14.15 | $13.45 | $14.15 | $25.00 | $141.5K | 1.4K | 130 |
| VKTX | CALL | SWEEP | NEUTRAL | 02/20/26 | $1.69 | $1.37 | $1.59 | $60.00 | $127.5K | 1.7K | 810 |
| VKTX | CALL | TRADE | BULLISH | 12/17/27 | $11.3 | $11.0 | $11.3 | $60.00 | $124.3K | 1.5K | 210 |
| VKTX | CALL | TRADE | BEARISH | 12/17/27 | $13.55 | $11.0 | $11.33 | $60.00 | $112.1K | 1.5K | 100 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Viking Therapeutics
- Currently trading with a volume of 2,560,725, the VKTX's price is down by -6.03%, now at $30.99.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 0 days.
What Analysts Are Saying About Viking Therapeutics
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $102.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $102.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
